Zymeworks Q1 net loss $31.7M, revenue $10M; cash $420.5M, runway into 2H27

Zymeworks Inc.

2024-Q1 EPS reported -$0.42 revenue$10,030,000

Revenue fell to $10.0M from $35.6M YoY due to transfer of zanidatamab responsibilities to Jazz.
Net loss widened to $31.7M vs $24.4M in Q1 2023; R&D expense decreased 30% to $32.0M.
Cash resources $420.5M; combined with anticipated milestones, funded into 2H 2027.
Partner Jazz completed rolling BLA submission to FDA for zanidatamab in BTC; Phase 3 breast cancer trial planned H2 2024.
On track for two IND submissions in 2024 for ZW191 and ZW171; Dr. Neil Gallagher joined board.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zymeworks Inc. reported three months ended March 31, 2024 results: revenue $10.0 million.

Period: three months ended March 31, 2024
Revenue: $10.0 million
Result: reported results

Exact text from the filing

Revenue was $10.0 million for the three months ended March 31, 2024 compared to $35.6 million for the same period in 2023.

View on SEC.gov

222 earnings releases filed in the last 30 days. Browse all earnings releases →

Zymeworks Inc. filing history →

Source: SEC EDGAR

accession 0001937653-24-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.